Login
$DGX
$262.21 +$0.00 (0.0%) After hours

$DGX 8-K SEC Filings

Filed On Filing
22 Oct 2026 8-K: Other Events

On October 21, 2026, Quest Diagnostics Incorporated (the “Company”) learned of unauthorized access to its Quanum LSM system, which certain clients use to place test orders, receive and look up results. The Company promptly initiated its ...

22 Oct 2026 8-K: Results of Operations and Financial Condition

SECAUCUS, N.J., October 22, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026.

06 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July 2027. Until then, effective November 1, 2026, Ms. Doherty will transition to a new role as Executive Vice Presiden...

23 Jul 2026 8-K: Results of Operations and Financial Condition

SECAUCUS, N.J., July 23, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.

21 May 2026 8-K: Submission of Matters to a Vote of Security Holders

(a) The following is a summary of the voting results for each matter presented to the stockholders at the 2026 Annual Meeting of Stockholders which was held on May 20, 2026.

08 May 2026 8-K: Entry into a Material Definitive Agreement

TWENTY-FOURTH SUPPLEMENTAL INDENTURE (this “Twenty-Fourth Supplemental Indenture”), dated as of May 6, 2026, between QUEST DIAGNOSTICS INCORPORATED, a Delaware corporation (the “Company”), and THE BANK OF NEW YORK MELLON, a New York bank...

01 May 2026 8-K: Other Events

Quest Diagnostics Incorporated, a Delaware corporation (the “Company”) confirms its agreement with Goldman Sachs & Co. LLC (“GS”), J.P. Morgan Securities LLC (“JPM”) and Mizuho Securities USA LLC (“Mizuho”) and each of the other underwri...

21 Apr 2026 8-K: Results of Operations and Financial Condition

SECAUCUS, N.J., April 21, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

12 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

10 Feb 2026 8-K: Results of Operations and Financial Condition; Other Events

SECAUCUS, N.J., February 10, 2026 -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Driving Sustainable Growth, Delivering Long-term Value Jim Davis Chairman, CEO, and President J.P. Morgan Healthcare Conference January 12, 2026 Quest Diagnostics

21 Oct 2025 8-K: Results of Operations and Financial Condition

SECAUCUS, N.J., October 21, 2025 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2025.

22 Jul 2025 8-K: Results of Operations and Financial Condition

SECAUCUS, N.J., July 22, 2025 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025.

22 May 2025 8-K: Submission of Matters to a Vote of Security Holders

(a) The following is a summary of the voting results for each matter presented to the stockholders at the 2025 Annual Meeting of Stockholders which was held on May 15, 2025.

22 Apr 2025 8-K: Results of Operations and Financial Condition

SECAUCUS, N.J., April 22, 2025 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.

19 Mar 2025 8-K: Regulation FD Disclosure

Driving Sustainable Growth, Delivering Long-term Value Jim Davis Chairman, CEO, and President Investor Day 2025 Quest Diagnostics

19 Mar 2025 8-K: Regulation FD Disclosure

Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR

30 Jan 2025 8-K: Results of Operations and Financial Condition; Other Events

SECAUCUS, N.J., January 30, 2025 -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2024.

22 Oct 2024 8-K: Results of Operations and Financial Condition

SECAUCUS, N.J., October 22, 2024 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2024.

29 Aug 2024 8-K: Other Events

On August 26, 2024, Quest Diagnostics Incorporated (the “Company”) announced that it has closed its previously announced acquisition of LifeLabs Inc. (“LifeLabs”), pursuant to the terms of an equity purchase agreement that the Company an...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support